Wegovy contains the same main ingredient as Ozempic, semaglutide, and is FDA-approved for weight loss in people with obesity or who are overweight with at least one weight-related condition. It is ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

A group of compounding ... semaglutide from the shortage list without warning and evidentiary support. The same companies sued the FDA in October over a similar decision the agency made with ...

Semaglutide injection products were first added to the FDA's drug shortage list for Wegovy in March 2022 and Ozempic in August 2022. A lawsuit filed by the compounding groups Outsourcing ...

The FDA also told compounding ... have been made available to it had the agency solicited public comment.” The lawsuit asks the court to vacate the FDA’s action of removing semaglutide from ...

A trade group representing compounding pharmacies has filed a lawsuit against the Food and Drug Administration (FDA) for removing semaglutide, the active ingredient in Ozempic, from its drug ...

Semaglutide is the main ingredient used to make Ozempic and Wegovy. The shortage allowed compounding pharmacies and other companies to step in and fill supply gaps with copycats of the drugs.

Another association that supports the industry, the Alliance for Pharmacy Compounding (APC), has stopped short of suing the FDA. Novo Nordisk's semaglutide shortage officially concludes in the US ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation ...

Adults with type 1 diabetes had greater declines in HbA1c and body weight 1 year after being prescribed semaglutide or tirzepatide. Randomized controlled trials are needed to assess efficacy and ...